NASDAQ · ADPT
Healthcare · Biotechnology
$24.74
Up+$0.28 (+1.14%)
Updated Aug 16, 2026, 4:40 AM
SID Score
6.3/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance
1M range · 20 trading sessions · Daily adjusted prices
ADPT closed at $24.74 after 20 trading sessions, up 13.17% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Aug 14, 2026 | $24.27 | $24.95 | $24.00 | $24.74 | 1.74M |
| Aug 13, 2026 | $25.54 | $25.54 | $24.41 | $24.46 | 1.54M |
| Aug 12, 2026 | $25.34 | $25.54 | $24.865 | $25.25 | 1.71M |
| Aug 11, 2026 | $25.38 | $26.09 | $25.0085 | $25.39 | 2.96M |
| Aug 10, 2026 | $24.90 | $26.155 | $24.65 | $25.45 | 2.37M |
| Aug 7, 2026 | $24.69 | $24.95 | $24.28 | $24.93 | 2.5M |
| Aug 6, 2026 | $24.58 | $24.58 | $23.41 | $23.60 | 2.47M |
| Aug 5, 2026 | $24.54 | $24.96 | $24.22 | $24.60 | 2.42M |
| Aug 4, 2026 | $23.60 | $24.62 | $23.03 | $24.55 | 3.29M |
| Aug 3, 2026 | $22.915 | $23.56 | $21.829 | $23.11 | 2.59M |
| Jul 31, 2026 | $24.568 | $24.568 | $22.41 | $22.57 | 2.99M |
| Jul 30, 2026 | $22.20 | $24.34 | $22.065 | $24.18 | 5.28M |
| Jul 29, 2026 | $22.48 | $23.0799 | $21.74 | $22.56 | 3.15M |
| Jul 28, 2026 | $22.72 | $22.9899 | $21.93 | $22.52 | 1.68M |
| Jul 27, 2026 | $22.70 | $23.00 | $21.78 | $22.54 | 2.44M |
| Jul 24, 2026 | $22.56 | $22.77 | $21.83 | $22.27 | 2.82M |
| Jul 23, 2026 | $21.95 | $22.91 | $21.95 | $22.31 | 2.76M |
| Jul 22, 2026 | $22.25 | $22.65 | $21.54 | $21.95 | 2.36M |
| Jul 21, 2026 | $21.63 | $22.60 | $20.90 | $22.58 | 3.51M |
| Jul 20, 2026 | $22.54 | $22.90 | $21.63 | $21.86 | 2.14M |
The latest Smart Investors Daily articles mentioning ADPT.
ADPT research
Company profile and research snapshot.
Adaptive Biotechnologies Corp is a company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease (MRD) in patients with multiple myeloma (MM), B cell acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CLL) and is also available as a CLIA-validated laboratory developed test (LDT) for patients with other lymphoid cancers, including diffuse large B-cell lymphoma (DLBCL).
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Aug 4, 2026 | Piper Sandler | Overweight | — |
| Jul 30, 2026 | TD Cowen | Buy | — |
| Jul 30, 2026 | Morgan Stanley | Equal-Weight | — |
| Jul 30, 2026 | Guggenheim | Buy | — |
| Jul 30, 2026 | BTIG | Buy | — |
No generated briefing is available yet.
Benzinga · Aug 4, 2026
Piper Sandler analyst David Westenberg maintains Adaptive Biotechnologies (NASDAQ:ADPT) with a Overweight and raises the price target from $20 to $27.5.
SeekingAlpha · Jul 31, 2026
Adaptive Biotechnologies (ADPT) pivots to pure-play MRD diagnostics as clonoSEQ adoption, margins & backlog surge.
Benzinga · Jul 30, 2026
Morgan Stanley analyst Tejas Savant maintains Adaptive Biotechnologies (NASDAQ:ADPT) with a Equal-Weight and raises the price target from $20 to $22.
Benzinga · Jul 30, 2026
TD Cowen analyst Dan Brennan maintains Adaptive Biotechnologies (NASDAQ:ADPT) with a Buy and raises the price target from $25 to $28.
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning ADPT.
